NCT06360042

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Therapy for Unresectable Hepatocellular Carcinoma: a Multicenter, Randomized, Open-label Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 111 (estimated)
• Sponsor: Peking University Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.

Conditions

• Unresectable Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Adebrelimab plus Apatinib	Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
DRUG	Adebrelimab plus Bevacizumab	Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
DRUG	Camrelizumab plus Apatinib	camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily

Timeline

• Start date: 2024-01-01
• Primary completion: 2027-03-31
• Completion: 2028-03-31
• First posted: 2024-04-11
• Last updated: 2024-04-22

Locations

1 site across 1 country: China